Research programme: TBK1/IKKe inhibitors - Domainex

Drug Profile

Research programme: TBK1/IKKe inhibitors - Domainex

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Domainex
  • Class Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors; TBK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease
  • Research Inflammation
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Cancer in United Kingdom (PO)
  • 09 Jul 2014 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)
  • 07 Apr 2014 This programme remains available for licensing as of 07 Apr 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top